AbbVie traded at $221.53 this Wednesday February 11th, decreasing $0.91 or 0.41 percent since the previous trading session. Looking back, over the last four weeks, AbbVie lost 0.68 percent. Over the last 12 months, its price rose by 14.78 percent. Looking ahead, we forecast AbbVie to be priced at 216.57 by the end of this quarter and at 197.23 in one year, according to Trading Economics global macro models projections and analysts expectations.
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.